Sangui Biotech International Inc (SBH) - Net Assets
Based on the latest financial reports, Sangui Biotech International Inc (SBH) has net assets worth €-1.01 Million EUR as of March 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€89.10K) and total liabilities (€1.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-1.01 Million |
| % of Total Assets | -1133.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Sangui Biotech International Inc - Net Assets Trend (2014–2022)
This chart illustrates how Sangui Biotech International Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sangui Biotech International Inc (2014–2022)
The table below shows the annual net assets of Sangui Biotech International Inc from 2014 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-06-30 | €-894.96K | -2.24% |
| 2021-06-30 | €-875.33K | -19.93% |
| 2020-06-30 | €-729.88K | -23.29% |
| 2019-06-30 | €-591.99K | -68.59% |
| 2018-06-30 | €-351.14K | -34.78% |
| 2017-06-30 | €-260.52K | -5.23% |
| 2016-06-30 | €-247.57K | +27.15% |
| 2015-06-30 | €-339.83K | -4770.62% |
| 2014-06-30 | €7.28K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sangui Biotech International Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 249868200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €33.12 Million | % |
| Other Components | €4.59 Million | % |
| Total Equity | €-239.13K | 100.00% |
Sangui Biotech International Inc Competitors by Market Cap
The table below lists competitors of Sangui Biotech International Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Clean Power Hydrogen PLC
LSE:CPH2
|
$421.46K |
|
Remington Resources Inc
V:RGM-H
|
$422.42K |
|
TPXimpact Holdings plc
LSE:TPX
|
$423.17K |
|
GAMES BOX S.A. ZY-10
F:ZN6
|
$423.88K |
|
GCL Global Holdings Ltd Warrants
NASDAQ:GCLWW
|
$417.45K |
|
Lion Group Holding Ltd
NASDAQ:LGHL
|
$417.43K |
|
Guess? Inc.
NYSE:GES
|
$417.21K |
|
Metgasco Ltd
AU:MEL
|
$415.96K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sangui Biotech International Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -223,528 to -239,128, a change of -15,600.
- Net loss of 59,310 reduced equity.
- New share issuances of 28,345 increased equity.
- Other factors increased equity by 15,365.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-59.31K | -24.8% |
| Share Issuances | €28.34K | +11.85% |
| Other Changes | €15.37K | +6.43% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Sangui Biotech International Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | €0.00 | €0.00 | x |
| 2018-06-30 | €0.00 | €0.00 | x |
| 2019-06-30 | €0.00 | €0.00 | x |
| 2020-06-30 | €0.00 | €0.00 | x |
| 2021-06-30 | €0.00 | €0.00 | x |
| 2022-06-30 | €0.00 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sangui Biotech International Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -85.72%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-170.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -276.29% | -1070.48% | 0.51x | 0.50x | €-1.48 Million |
| 2015 | -315.00% | -552.84% | 1.04x | 0.55x | €-727.07K |
| 2016 | -124.17% | -879.57% | 0.43x | 0.32x | €-456.28K |
| 2017 | -88.85% | -456.71% | 0.72x | 0.27x | €-343.75K |
| 2018 | -74.44% | -261.57% | 0.76x | 0.38x | €-228.92K |
| 2019 | -657.63% | -367.70% | 1.11x | 1.61x | €-328.50K |
| 2020 | 0.00% | -666.58% | 0.23x | 0.00x | €-184.45K |
| 2021 | 0.00% | -303.26% | 0.49x | 0.00x | €-176.54K |
| 2022 | 0.00% | -85.72% | 0.53x | 0.00x | €-35.40K |
Industry Comparison
This section compares Sangui Biotech International Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,865,474,562
- Average return on equity (ROE) among peers: -97.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sangui Biotech International Inc (SBH) | €-1.01 Million | -276.29% | N/A | $419.80K |
| Blueberries Medical Corp (1OA) | $3.89 Million | -127.00% | 0.87x | $1.16 Million |
| 26U (26U) | $-312.00K | 0.00% | 0.00x | $128.79 Million |
| 27N0 (27N0) | $10.67 Million | -0.29% | 0.00x | $566.23K |
| iAnthus Capital Holdings Inc (2IA) | $-22.40 Million | 0.00% | 0.00x | $4.08 Million |
| Revive Therapeutics Ltd (31R) | $10.65 Million | -59.34% | 0.34x | $397.77K |
| AYR WELLNESS INC.RES.VTG. (3KJB) | $570.65 Million | -47.74% | 1.56x | $5.84 Million |
| Vibe Growth Corporation (3ST) | $-5.22 Million | 0.00% | 0.00x | $214.59K |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| China Resources Pharmaceutical Group Limited (640) | $98.09 Billion | 3.42% | 1.63x | $4.42 Billion |
About Sangui Biotech International Inc
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and woun… Read more